Physician profile
Jeffrey L Shy
NPI 1831246503
$5,902.31
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $2,640 · 2021: $3,060.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $679.68 | 2020-2021 | |
| Allergan, INC. | $591.92 | 2020-2021 | |
| Biogen, INC. | $419.24 | 2019-2021 | |
| Abbvie INC. | $343.02 | 2020-2021 | |
| Ucb, INC. | $337.07 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $264.84 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $233.26 | 2020-2021 | |
| Csl Behring | $224.19 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $218.06 | 2019-2021 | |
| Lilly USA, LLC | $189.20 | 2020-2021 | |
| Mdd US Operations, LLC | $174.93 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $174.65 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $147.82 | 2021 | |
| Acadia Pharmaceuticals INC | $124.46 | 2020-2021 | |
| Emd Serono, INC. | $114.08 | 2019-2021 |
Show all 53 companies
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Shy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.